Supersolubilization and amorphization of a model basic drug, haloperidol, by interaction with weak acids

Pharmaceutical Research

Volumn 30, Issue 6, 2013, Pages 1561-1573

  Singh, Saumya ^a,c   Parikh, Tapan ^a   Sandhu, Harpreet K ^b   Shah, Navnit H ^b   Malick, A Waseem ^b   Singhal, Dharmendra ^b   Serajuddin, Abu T M ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c Aptuit Inc   (United States)

Author keywords

acid base interaction; amorphous system; basic drug; dissolution rate; haloperidol; solubility; weak acid

Indexed keywords

CITRIC ACID; FUMARIC ACID; HALOPERIDOL; MALIC ACID; TARTARIC ACID;

ACID BASE BALANCE; ARTICLE; DRUG DETERMINATION; DRUG SOLUBILITY; DRUG STABILITY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SOLUBILIZATION; THERMAL ANALYSIS; X RAY DIFFRACTION;

ACIDS; DRUG STABILITY; HALOPERIDOL; HYDROGEN-ION CONCENTRATION; SALTS; SOLUBILITY; SOLUTIONS; WATER;

EID: 84877789049     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-0994-7     Document Type: Article

References (29)

1. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235-49.
2. Lipinski CA. Poor aqueous solubility - an industry wide problem in drug discovery. Am Pharm Rev. 2002;5:82-5.
3. Lipinski CA. Compound properties and drug quality. In: Wermuth CG, editor. The practice of medicinal chemistry. Chapter 22. 3rd ed. London: Academic; 2008. p. 481-90. 4.
4. Vasanthavada M, Tong WQ, Serajuddin ATM. Development of solid dispersions for poorly water-soluble drug. In: Liu R, editor. Water-insoluble drug formulations. 2nd ed. New York: Informa Healthcare; 2008. p. 149-84.
5. Serajuddin ATM, Li P, Haefele T. Development of lipid-based drug delivery systems for poorly water-soluble drugs as viable oral dosage forms - present status and future prospects. Am Pharm Rev. 2008;11:34.
6. General notices and requirements (section 5:30). In: United States Pharmacopoeia-National Formulary USP34-NF29. Rockville: United States Pharmacopoeial Convention; 2011, p. 6.
7. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18(2):113-20.
8. Kesisoglou F, Panmai S, Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59(7):631-44.
9. Li P, Zhao L. Developing early formulations: practice and perspective. Int J Pharm. 2007;341(1-2):1-19.
10. Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59(7):603-16.
11. Hancock BC, Parks M. What is the solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17(4):397-404.
12. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;48(1):27-42.
13. Bhugra C, Pikal MJ. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci. 2008;97(4):1329-49.
14. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281-302.
15. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88(10):1058-66.
16. Porter C, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature Rev. 2007;6(3):231-48.
17. Prajapati HN, Dalrymple DM, Serajuddin ATM. A comparative evaluation of mono-, di-and triglyceride of medium chain fatty acids by lipid/surfactant/water phase diagram, solubility determination and dispersion testing for application in pharmaceutical dosage form development. Pharm Res. 2012;29(1):285-305.
18. Patel DP, Li P, Serajuddin ATM. Enhanced microemulsion formation in lipid-based drug delivery systems by combining mono-esters of medium chain fatty acids with di- and tri-esters. J Excipients Food Chem. 2012;3(2):29-44.
19. Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol. 2010;62(11):1569-79.
20. Kim Y, Oksanen DA, Massefski Jr W, Blake JF, Duffy EM, Chrunyk B. Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether. J Pharm Sci. 1998;87(12):1560-7.
21. Thombre AG, Herbig SM, Alderman JA. Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect. Pharm Res. 2011;289(12):3159-70.
22. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3-4):278-87.
23. Li S, Wong SM, Sethia S, Almoazen H, Joshi YM, Serajuddin ATM. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm Res. 2005;22(4):628-35.
24. Greco K, Mcnamara DP, Bogner R. Solution-mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug. J Pharm Sci. 2011;100(7):2755-68.
25. Kramer S, Flynn G. Solubility of organic hydrochlorides. J Pharm Sci. 1972;61(12):1896-904.
26. Anderson BD, Flora KP. Preparation of water-soluble compounds through salt formation. In: Wermuth CG, editor. The practice of medicinal chemistry. 1st ed. London: Academic; 1996. p. 739-54.
27. Pudipeddi M, Serajuddin ATM, Grant DJW, Stahl P. Salt selection strategies. In: Stahl PH, Wermuth CG, editors. IUPAC handbook of pharmaceutical salts: properties, selection, and use. Chapter 6. Zurich: Verlag Helvetica Chimica Acta; 2002. p. 135-60.
28. Serajuddin ATM, Pudipeddi M. Solubility and dissolution of weak acids, bases and salts. In: Stahl PH, Wermuth CG, editors. IUPAC handbook of pharmaceutical salts: properties, selection, and use. Chapter 2. Zurich: Verlag Helvetica Chimica Acta; 2002. p. 19-39.
29. The Merck Index, an encyclopedia of chemicals, drugs and biologicals. 14th ed. Rahway (NJ): Merck & Co; 2006, p. 2326, 4287, 5707, 9070.